Tresiba Compounding Legal Status: What Patients and Prescribers Need to Know

What Is Tresiba and Why Does Its Regulatory Status Matter?

Tresiba is the brand name for insulin degludec, a basal insulin analog manufactured by Novo Nordisk. The FDA granted approval on September 25, 2015, under NDA 203314, covering both the U-100 and U-200 formulations delivered via FlexTouch pen. The FDA approval package and label history are publicly searchable at Drugs@FDA.

Why Regulatory Status Is Not a Technicality

For any FDA-approved drug, regulatory status determines whether a licensed compounding pharmacy may legally prepare a copy. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding is permitted only for a patient with a valid prescription, and only when the drug is not "essentially a copy" of a commercially available product. The FDA's guidance on compounding from essentially-a-copy provisions is codified here.

Tresiba is commercially available in all standard pharmacies. No national shortage exists. That combination eliminates both the 503A "essentially a copy" loophole and any 503B outsourcing facility pathway.

The Clinical Stakes

Getting this wrong is not a paperwork problem. Insulin is a high-alert medication with a narrow therapeutic index. Concentration errors in compounded insulins have produced life-threatening hypoglycemia. The FDA's MedWatch database documents multiple sentinel events tied to compounded insulins with incorrect unit concentrations.

FDA Approval History and NDA 203314

Approval Timeline

The FDA approved Tresiba (NDA 203314) on September 25, 2015, for adults with type 1 and type 2 diabetes. The full label and all subsequent labeling revisions are posted on Drugs@FDA. A pediatric indication for patients aged 1 year and older was added following the completion of SWITCH PP, a pediatric crossover trial. PubMed PMID 31356626 covers the pediatric SWITCH PP data.

Pre-Approval Clinical Package

The FDA's approval was based on the BEGIN clinical trial program, which enrolled more than 10,000 patients across multiple phase 3 trials. BEGIN Once Long (N=1,030) compared insulin degludec once daily to insulin glargine U-100 once daily over 52 weeks in type 2 diabetes, showing comparable HbA1c reduction with a significantly lower rate of confirmed nocturnal hypoglycemia. BEGIN Once Long is indexed at PubMed PMID 22243334.

The FDA required a post-market cardiovascular outcomes trial (CVOT) as a condition of approval, consistent with the agency's 2008 CVOT guidance for diabetes drugs. That requirement produced the DEVOTE trial.

The Tresiba Prescribing Label: Key Requirements

Black-Box Warning

All insulin products carry an FDA-mandated black-box warning for hypoglycemia. The Tresiba label states: "Hypoglycemia is the most common adverse reaction of insulin therapy, including Tresiba, and may be life threatening." The current prescribing information is available through FDA's labeling repository.

Dosing Flexibility Language

One clinically significant label feature is dosing flexibility. The label permits dosing at any time of day, with the ability to change the injection time as needed, provided at least 8 hours separate consecutive doses. This is a direct consequence of the drug's greater-than-42-hour duration of action and flat pharmacodynamic profile. The pharmacokinetic basis for this flexibility is described in the labeling and supported by euglycemic clamp data published at PubMed PMID 23906321.

Concentration Warning

The label explicitly warns that Tresiba U-200 (200 units/mL) delivers twice the insulin dose per unit volume compared with U-100. Healthcare providers are instructed never to convert doses between U-100 and U-200 formulations using volume. This is a direct patient-safety rationale for why compounded versions, which may not replicate exact concentration, present unacceptable risk.

Contraindications and Precautions

The label lists hypoglycemia episodes during hypoglycemic episodes and hypersensitivity to insulin degludec or any of its excipients as contraindications. FDA labeling contraindications for insulin analogs are summarized in the prescribing information available at accessdata.fda.gov.

DEVOTE Trial: Cardiovascular Safety Evidence

Trial Design

DEVOTE (A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events) was a double-blind, treat-to-target, randomized controlled trial. It enrolled 7,637 patients with type 2 diabetes and high cardiovascular risk across 20 countries. DEVOTE was published in the New England Journal of Medicine in 2017 and is indexed at PubMed PMID 28605603.

Primary Cardiovascular Outcome

The primary endpoint was three-point MACE (major adverse cardiovascular events: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke). Insulin degludec produced a MACE hazard ratio of 0.91 (95% CI 0.78 to 1.06, P<0.001 for non-inferiority) compared with insulin glargine U-100. This met the FDA's pre-specified non-inferiority margin of 1.30. DEVOTE full results: PubMed PMID 28605603.

Hypoglycemia Secondary Endpoint

The secondary hypoglycemia analysis from DEVOTE is particularly relevant for clinical decision-making. Insulin degludec produced a 40% lower rate of severe hypoglycemia (rate ratio 0.60, 95% CI 0.48 to 0.76, P<0.001) and a 53% lower rate of nocturnal severe hypoglycemia (rate ratio 0.47, 95% CI 0.31 to 0.73, P<0.001) compared with glargine U-100. The hypoglycemia outcomes from DEVOTE, published as DEVOTE 2, are at PubMed PMID 28605602.

These numbers matter for the compounding discussion: any compounded substitute that does not reliably deliver the exact pharmacodynamic profile of insulin degludec cannot be assumed to carry the same hypoglycemia advantage.

What DEVOTE Tells Regulators

The FDA reviewed DEVOTE data as part of its post-market surveillance obligations. FDA's post-market drug safety reporting framework is described at the FDA Safety page. DEVOTE's cardiovascular non-inferiority result supported retention of the existing label rather than any new restriction.

Compounding Legal Status: The Full Regulatory Analysis

Section 503A: Individual Patient Compounding

Under 21 U.S.C. 353a (Section 503A of the FD&C Act), a licensed pharmacist may compound a drug for an identified individual patient if several conditions are met. Among those: the compounded drug must not be "essentially a copy" of a commercially available drug, and it must not appear on the FDA's list of drugs withdrawn or removed from the market for safety reasons. The FDA's 503A guidance document is available at fda.gov.

Tresiba is commercially available nationwide. A compounded version of insulin degludec would, in nearly all circumstances, qualify as essentially a copy. No specific medically necessary reason, such as removal of an allergen not present in the commercial product, has been recognized by the FDA for insulin degludec.

Section 503B: Outsourcing Facilities

Section 503B governs FDA-registered outsourcing facilities, which may compound drugs without patient-specific prescriptions under certain conditions. The FDA's 503B bulks list, which enumerates substances outsourcing facilities may use, is published at fda.gov. Insulin degludec does not appear on the 503B nominated substances list as an approved bulk drug substance for outsourcing facility compounding.

Shortage-Based Exceptions

The FDA maintains a Drug Shortage database. Current shortage listings are searchable at accessdata.fda.gov/scripts/drugshortages. As of the date of this article's review, Tresiba (insulin degludec) does not appear on that list. Shortage-based compounding exceptions therefore do not apply.

HealthRX Clinical Decision Framework: Is a Compounded Insulin Degludec Ever Appropriate?

The following three-question screen summarizes the legal and clinical analysis for any prescriber or pharmacist who receives a request for compounded insulin degludec.

1. Is Tresiba currently on the FDA Drug Shortage Database? If no, compounding is not authorized under shortage provisions.
2. Does the patient have a documented allergy or intolerance to a specific excipient in the commercial Tresiba formulation that cannot be managed by switching to another approved basal insulin? If no, the "essentially a copy" exclusion applies under 503A.
3. Is the compounder a registered 503B outsourcing facility, and is insulin degludec on the current 503B bulks list? If no, 503B does not provide cover.

If all three answers are no, compounding insulin degludec is not legally defensible under current federal law.

ADA Guidelines and Place in Therapy

ADA Standards of Care 2024

The American Diabetes Association's Standards of Care in Diabetes 2024 place basal insulin analogs, including insulin degludec, in the treatment algorithm for both type 1 and type 2 diabetes when glycemic targets are not achieved with oral agents or when insulin is required from diagnosis. The full ADA Standards of Care 2024 are published in Diabetes Care and accessible at diabetesjournals.org.

The ADA guideline states: "Insulin degludec and insulin glargine U-300 have been shown to have lower rates of hypoglycemia compared with insulin glargine U-100 and may be preferred in patients at high risk of hypoglycemia." This directly echoes the DEVOTE secondary endpoint data.

Preferred Patient Populations

Insulin degludec's flat pharmacodynamic profile and greater-than-42-hour action duration make it particularly well-suited for patients with erratic schedules, shift workers, or those who have experienced recurrent nocturnal hypoglycemia on other basal insulins. A systematic review of basal insulin pharmacokinetics supporting these distinctions is at PubMed PMID 27301653.

Biosimilar and Reference Product Status

Insulin degludec is the reference product for any future biosimilar applicants under the Biologics Price Competition and Innovation Act (BPCIA). FDA's biosimilar development guidance is at fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars. No FDA-approved biosimilar for insulin degludec has been granted as of the last review date of this article. The reference product status is an additional argument against compounding: biosimilar applicants must demonstrate analytical and clinical similarity through a rigorous FDA pathway. A compounded preparation undergoes no such evaluation.

Post-Market Safety Surveillance

FDA Sentinel System

The FDA's Sentinel System performs active post-market surveillance using claims and electronic health record data across tens of millions of covered lives. The Sentinel System is described at fda.gov/safety/fdas-sentinel-initiative. Post-market safety signals for insulin degludec reviewed through Sentinel have not produced any new label restrictions since the DEVOTE data were incorporated. The most recent label revision (2021) did not add new contraindications.

EMA Post-Market Experience

The European Medicines Agency granted marketing authorization for Tresiba in January 2013, more than two years before the FDA. The EMA EPAR for insulin degludec is publicly available at ema.europa.eu. Post-authorization safety studies conducted in the EU have confirmed the hypoglycemia profile observed in DEVOTE and the BEGIN program, with no new safety signals of regulatory concern identified through 2024 periodic safety update reports.

Real-World Evidence

A large Danish real-world cohort (N=8,956 patients initiating basal insulin) published in Diabetes Care found that insulin degludec was associated with a 30% lower rate of severe hypoglycemia requiring emergency department contact compared with insulin glargine U-100 (incidence rate ratio 0.70, 95% CI 0.56 to 0.87). This real-world study is indexed at PubMed PMID 30237246. These real-world findings further support the label's hypoglycemia differentiation claims and underscore why pharmacokinetic fidelity, not just nominal labeling, matters for patient outcomes.

What Prescribers Should Document

Prescribing for Brand-Name Tresiba

When prescribing insulin degludec, the prescription should specify the brand name Tresiba, the concentration (U-100 or U-200), the delivery device (FlexTouch pen), and, where state law permits, "dispense as written" or equivalent notation. State-level DAW requirements vary; the AAFP provides a summary of prescribing authority by state at aafp.org.

Specifying brand name and concentration prevents inadvertent dispensing of a compounded preparation or a substitution error involving the U-100 versus U-200 formulations.

Responding to Pharmacy Substitution Requests

If a pharmacy contacts the prescriber requesting authorization to substitute a compounded insulin degludec, the prescriber should document in the chart that no substitution was authorized, that no clinical rationale for compounding exists (absent a documented excipient allergy), and that the patient was counseled on the legal and safety issues. A brief note citing NDA 203314 approval status and the 503A essentially-a-copy provision is sufficient legal support.

Counseling Patients on Online Pharmacy Offers

Some direct-to-consumer platforms have advertised "compounded insulin degludec" or products described as "insulin degludec equivalent." Patients should be counseled that no such product is FDA-approved, that purity and concentration cannot be verified, and that the FDA has taken enforcement action against compounders marketing unapproved insulin preparations. FDA enforcement actions against unlawful compounders are catalogued at fda.gov/drugs/human-drug-compounding/compounding-compliance-actions-and-activities.

Practical Prescribing Considerations

Titration Protocol

The Tresiba label recommends starting adults with type 2 diabetes at 10 units once daily, then titrating by 2 units every 3 days to reach fasting glucose targets. The FDA label titration guidance is at accessdata.fda.gov. For type 1 diabetes, the starting dose is weight-based at approximately one-third of total daily insulin requirements.

Switching From Other Basal Insulins

Patients switching from insulin glargine U-100 convert on a unit-for-unit basis. Patients switching from insulin glargine U-300 or insulin detemir may require dose adjustments; the label advises more frequent monitoring during the transition period. A pharmacodynamic switching study supporting these recommendations is at PubMed PMID 25613476.

Storage

Unopened Tresiba pens may be stored at room temperature (below 86°F / 30°C) for up to 56 days or refrigerated until the expiration date. In-use pens should not be refrigerated. These storage parameters are defined in the FDA label and have patient-safety implications for any compounded preparation, which would require separate stability validation.